These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26967009)

  • 1. Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.
    Caso F; Ramonda R; Del Puente A; Darda MA; Cantarini L; Peluso R; Esposito C; Ortolan A; Fiocco U; Punzi L; Scarpa R; Costa L
    Clin Exp Rheumatol; 2016; 34(3):507-12. PubMed ID: 26967009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis.
    Polachek A; Korobko U; Mader-Balakirski N; Arad U; Levartovsky D; Kaufman I; Anouk M; Litinsky I; Wigler I; Mendelson E; Paran D; Matz H; Caspi D; Mandelboim M; Elkayam O
    Clin Exp Rheumatol; 2015; 33(2):181-6. PubMed ID: 25738420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
    Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
    J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
    Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
    J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate.
    Scarpa R; Peluso R; Atteno M; Manguso F; Spanò A; Iervolino S; Di Minno MN; Costa L; Del Puente A
    Clin Rheumatol; 2008 Jul; 27(7):823-6. PubMed ID: 18030515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
    Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
    Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
    Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
    J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet.
    Simon P; Pfoehler C; Bergner R; Schreiber M; Pfreundschuh M; Assmann G
    Clin Exp Rheumatol; 2012; 30(1):45-50. PubMed ID: 22274638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
    Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
    J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis.
    Carvalho PD; Duarte C; Vieira-Sousa E; Cunha-Miranda L; Avila-Ribeiro P; Santos H; Bernardes M; Santos MJ; Cerqueira M; Mateus M; Nero P; Águeda A; Silva JA; Machado P
    Acta Reumatol Port; 2017; 42(1):55-65. PubMed ID: 27750274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.
    Di Minno MN; Iervolino S; Peluso R; Scarpa R; Di Minno G;
    Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):705-12. PubMed ID: 21212403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA.
    Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ
    Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.